OCRF & Ovarian Cancer National Alliance are now one strong, united, inspiring voice!
Ovarian Cancer Research Fund (OCRF) and the Ovarian Cancer National Alliance (OCNA) have led the way in advocacy, research and support for patients and their families for over 22 years. As of January 2016, we are pleased to announce we are joining together to form Ovarian Cancer Research Fund Alliance (OCRFA), the largest global organization dedicated to advancing ovarian cancer research while supporting women and their families. Read the exciting news!


2013 Ann Schreiber Grant Recipient – Pradeep Chaluvally-Raghavan

Pradeep Chaluvally-Raghavan, PhD
MD Anderson Cancer Center
Role of microRNAs in the 3q26 Amplicon in Ovarian Cancer Pathophysiology and Therapy

Project Summary

Epithelial ovarian cancers are a complex group of tumors that arise from multiple different precursor tissues. High grade serous ovarian cancer, the most common and most lethal form of ovarian cancer is driven primarily by mutations in p53 and DNA copy number abnormalities (CNA). Our lab demonstrated that the consequences of 3q26.2 CNA are complex resulting in amplification and aberrant function of several tumor promoting gens such as PIK3CA, PKC?, Snon, and Mecom (EVI1 and MDS1/EVI1). However microRNAs overexpressed due to genomic amplification were not well studied. In his study Dr.Chaluvally-Raghavan focus oncogenic roles of tumor driver microRNAs amplified and overexpressed in ovarian cancers. We believe our results will bring new microRNA biomarkers and new therapeutic opportunities to target the oncogenes were previously considered undruggable.


Pradeep Chaluvally-Raghavan is a Postdoctoral Fellow working under the mentorship of Dr. Gordon Mills in the Department of Systems Biology at The University of Texas MD Anderson Cancer Center in Houston, Texas. Dr.Chaluvally-Raghavan completed his Ph.D from the University of Calicut in India. During his graduate training his research focused on the roles of NF-kB transcription factor in melanoma metastasis. Before joining to Dr. Mill’s lab, he worked as a postdoctoral fellow in the lab of Dr. Yosef Yardmen at the Weizmann Institute of Science, where he explored the mechanisms underlying the role of HER2 oncogene in the transition of normal cells to Ductal Carcinoma In situ (DCIS), then invasive cancer.

Dr.Chaluvally-Raghavan earned multiple awards including Trainee Excellence award, Amgen Best Poster Award and Abstract Winner Award from MD Anderson Cancer Center during the training cycle of 2011 to 2012. In 2009 Dr. Chaluvally Raghavan was awarded an AACR Avon Foundation International Scholar-in-Training Award. As a recipient of the Ann Schreiber Program for Excellence of Ovarian Cancer Research Foundation, Dr. Chaluvally-Raghavan is on his way to establishing an independent career in ovarian cancer research. He is currently interested in microRNAs and anti-microRNAs based therapy to combat ovarian cancer.

This grant was made possible in part through generous support from Hope for Heather.